Andrx To Exit Brand Business, Focus On Generic Drugs

Law360, New York (January 5, 2005, 12:00 AM EST) -- Andrx Corp., a leading generic drug maker in the U.S., has vowed to exit its loss-making brand business and concentrate completely on generic drugs and the pharmaceutical distribution business.

The Florida-based drug maker said Monday that its board of directors had approved a plan to revise its business strategy and focus on the development of controlled-release pharmaceuticals and distribution.

The company plans to divest or seek other strategic alternatives for its brand pharmaceutical business and has engaged Banc of America Securities LLC to solicit offers for...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.